biden glp-1 wanted Medicaid to pay for weight-loss drugs. Trump just said it doesn't have to. • Stateline Biden wants to expand access
Description
CU Cancer Center member Bryan Haugen, MD, breaks down the science behind the FDA warning on the GLP-1 weight-loss medications.
Background Despite the effectiveness of glucagon-like peptide-1 agonist (GLP-1A) in the treatment of diabetes, its large molecular weight and high hydrophilicity result in poor cellular permeability, thus limiting its oral bioavailability
Berberine
Looking ahead, their action on the brain is prompting research to gauge their value in curbing drug, alcohol, and nicotine cravings
